載入中
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
前收盤價
US$5.74
−US$0.44 · -7.12%
盤後
US$5.6503
−US$0.0897 · -1.56%
10月8日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日內區間
目前US$5.74
52週區間
目前US$5.74
盤中時間採用ET。市場資料可能有所延遲。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日內區間
目前US$5.74
52週區間
目前US$5.74
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 2499萬 USD | 973萬 USD |
| 銷貨成本 | 638.1萬 USD | — | — | — | — |
| 毛利 | −638.1萬 USD | — | — | 2499萬 USD | 973萬 USD |
| 研究與開發 | 9912.7萬 USD | 9932.3萬 USD | 1.06億 USD | 7124.6萬 USD | 4894.3萬 USD |
| 銷售、一般及管理費用 | 2298.7萬 USD | 2829.2萬 USD | 2653.3萬 USD | 2629.5萬 USD | 2222萬 USD |
| 營業費用 | 1.16億 USD | 1.28億 USD | 1.52億 USD | 9754.1萬 USD | 7116.3萬 USD |
| 利息收入 | 577.7萬 USD | 1071.4萬 USD | 997.8萬 USD | 376萬 USD | 9.1萬 USD |
| 利息支出 | 3.6萬 USD | 4000 USD | 2.5萬 USD | 8萬 USD | 17.6萬 USD |
| 折舊和攤銷 | 638.1萬 USD | 646.8萬 USD | 609.8萬 USD | 266.7萬 USD | 153.8萬 USD |
| 營業利益 | −1.22億 USD | −1.28億 USD | −1.52億 USD | −7255.1萬 USD | −6143.3萬 USD |
| 淨利 | −1.17億 USD | −1.17億 USD | −1.43億 USD | −6979萬 USD | −6199.9萬 USD |
公司資料更新於 2026年10月9日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年12月30日 | 1:16 | — | — |
股票分割 | 2020年9月16日 | 1:7 | — | — |
已生效 2025年12月30日
1:16
已生效 2020年9月16日
1:7
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI211.61萬0.00%2.3兆 USD0.03%US$379.56-0.39%
Vanguard Extended Market ETFVXF86.05萬0.00%954億 USD0.05%US$233.13-0.15%
iShares Micro-Cap ETFIWC14.02萬0.01%13.19億 USD0.60%US$182.79-0.31%
Dimensional - US Small Cap ETFDFAS11.51萬0.00%336.6億 USD0.31%US$78.10+0.23%
U.S. Micro Cap Portfolio ETFDFMC10.71萬0.00%75.2億 USD0.43%US$57.70+0.35%
Avantis U.S. Small Cap Equity ETFAVSC4.08萬—30.38億 USD0.25%US$69.96+0.47%
U.S. Vector Equity Portfolio ETF Class SharesDXUV2954.040.00%61.57億 USD0.26%US$68.11+0.22%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
